EA202091974A1 - Связывающие bcma антитела и их применение - Google Patents

Связывающие bcma антитела и их применение

Info

Publication number
EA202091974A1
EA202091974A1 EA202091974A EA202091974A EA202091974A1 EA 202091974 A1 EA202091974 A1 EA 202091974A1 EA 202091974 A EA202091974 A EA 202091974A EA 202091974 A EA202091974 A EA 202091974A EA 202091974 A1 EA202091974 A1 EA 202091974A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bcma
antibodies
patient
binders
application
Prior art date
Application number
EA202091974A
Other languages
English (en)
Inventor
Махан Аббасиан
Генри Чан
Кандасами Харихаран
Дзеонгхоон Сунь
Эндрю Вермсер
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of EA202091974A1 publication Critical patent/EA202091974A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предложены антитела, которые связывают антиген созревания В-клеток (BCMA), а также способы истощения экспрессирующих BCMA клеток у пациента, нуждающегося в этом, включающие в себя введение терапевтически эффективного количества антител или объекта, содержащего их BCMA-связывающий фрагмент. Предложены способы лечения связанных с В-клетками заболеваний, ассоциированных с экспрессией BCMA, у пациента, нуждающегося в этом, включающие в себя введение пациенту терапевтически эффективного количества антител или объекта, содержащего их BCMA-связывающий фрагмент.
EA202091974A 2018-02-21 2019-02-20 Связывающие bcma антитела и их применение EA202091974A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633152P 2018-02-21 2018-02-21
PCT/US2019/018698 WO2019164891A1 (en) 2018-02-21 2019-02-20 Bcma-binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202091974A1 true EA202091974A1 (ru) 2020-12-08

Family

ID=65686040

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091974A EA202091974A1 (ru) 2018-02-21 2019-02-20 Связывающие bcma антитела и их применение

Country Status (15)

Country Link
US (2) US11401336B2 (ru)
EP (1) EP3755718A1 (ru)
JP (1) JP2021514193A (ru)
KR (1) KR20200123155A (ru)
CN (1) CN112272675A (ru)
AR (1) AR115257A1 (ru)
AU (1) AU2019223076A1 (ru)
BR (1) BR112020017053A2 (ru)
CA (1) CA3092037A1 (ru)
EA (1) EA202091974A1 (ru)
IL (1) IL276548A (ru)
MX (1) MX2020008718A (ru)
SG (1) SG11202007495SA (ru)
TW (1) TW202000701A (ru)
WO (1) WO2019164891A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502652A (ja) * 2019-11-18 2023-01-25 ヤンセン バイオテツク,インコーポレーテツド 抗cd79キメラ抗原受容体、car-t細胞、及びそれらの使用
IL297716A (en) * 2020-04-30 2022-12-01 Bristol Myers Squibb Co Preparations for the treatment of side effects related to cytokines
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
AU5305796A (en) 1995-03-10 1996-10-02 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
PT2070920E (pt) 1996-07-24 2011-03-31 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimidas e 1-oxoisoindolinas substituídas e método de redução dos níveis de tnf-alfa
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
DK0918746T3 (da) 1996-08-12 2003-08-04 Celgene Corp Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
KR20060036124A (ko) 1998-03-16 2006-04-27 셀진 코포레이션 염증성 사이토카인 억제제용2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그제조방법 및 그 용도
BR0010042A (pt) 1999-03-18 2002-01-15 Celgene Corp 1-oxo-e 1,3-dioxoisoindolinas substituìdas e seu uso em composições farmacêuticas para a redução de nìveis de citocina inflamatória
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
BRPI0518793A2 (pt) 2004-12-01 2008-12-09 Celgene Corp mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
BRPI0607239A2 (pt) 2005-01-25 2009-08-25 Celgene Corp usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples
JP5578785B2 (ja) 2005-08-31 2014-08-27 セルジーン コーポレイション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
UA94964C2 (ru) 2006-09-26 2011-06-25 Селджин Корпорэйшн Производные 5-замещенного хиназолинона, композиция, которая их содержит, и их применение
JP2012502967A (ja) * 2008-09-19 2012-02-02 メディミューン,エルエルシー ソニック・ヘッジホッグホモログに対する抗体およびその使用
WO2011100380A1 (en) 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
SI2683708T1 (en) 2011-03-11 2018-05-31 Celgene Corporation 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINASOLIN-3-YL) -PYPERIDIN-2,6-DION, AND THEIR PHARMACEUTICAL COMPOSITION AND TYPES OF USE
CN106279418A (zh) 2011-05-27 2017-01-04 葛兰素集团有限公司 Bcma(cd269/tnfrsf17)结合蛋白
WO2014004990A2 (en) 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
WO2015166073A1 (en) * 2014-04-30 2015-11-05 Max-Delbrück-Centrum für Molekulare Medizin Humanized antibodies against cd269 (bcma)
CA2955386A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN112358551B (zh) 2014-12-12 2024-02-02 2赛文缇生物公司 Bcma嵌合抗原受体
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
BR112017019914A2 (pt) 2015-04-13 2018-06-19 Pfizer receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
AU2016248946B2 (en) 2015-04-13 2022-03-10 Pfizer Inc. Therapeutic antibodies and their uses
ES2777602T3 (es) 2015-08-03 2020-08-05 Engmab Sàrl Anticuerpos monoclonales contra el antígeno de maduración de células b humanas (BCMA)
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
CA3019135A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Bcma binding molecules and methods of use thereof
MX2018016404A (es) * 2016-06-21 2019-10-15 Teneobio Inc Anticuerpos de union a cd3.

Also Published As

Publication number Publication date
WO2019164891A1 (en) 2019-08-29
US20200399386A1 (en) 2020-12-24
WO2019164891A9 (en) 2020-09-17
TW202000701A (zh) 2020-01-01
CA3092037A1 (en) 2019-08-29
MX2020008718A (es) 2020-12-07
EP3755718A1 (en) 2020-12-30
CN112272675A (zh) 2021-01-26
AU2019223076A1 (en) 2020-10-08
IL276548A (en) 2020-09-30
BR112020017053A2 (pt) 2020-12-15
SG11202007495SA (en) 2020-09-29
AR115257A1 (es) 2020-12-16
KR20200123155A (ko) 2020-10-28
US20220324991A1 (en) 2022-10-13
US11401336B2 (en) 2022-08-02
JP2021514193A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
EA202091974A1 (ru) Связывающие bcma антитела и их применение
EA202090739A1 (ru) Белки, связывающие антиген созревания в-клеток
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
EA202190773A1 (ru) CD1d ИММУНОГЛОБУЛИН ДВОЙНОГО ДЕЙСТВИЯ
EA202092668A1 (ru) Антитела к ил-11
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
EA201691858A1 (ru) Композиции антител для лечения опухолей
WO2015112805A8 (en) Human antibodies to pd-l1
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
EA201892774A1 (ru) Антитела
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201491452A1 (ru) Антитела к asic1 и их применение
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201591762A1 (ru) Человеческие антитела к grem1
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
EA201690503A1 (ru) Антитела
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.